

Tianeptine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study

Submission date 21/09/2006	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 05/10/2006	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 05/10/2006	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Ferran J García-Fructuoso

Contact details
Paseo Manuel Girona, 33
Servicio de Reumatología
Clínica CIMA
Barcelona
Spain
08034
ferran.garcia@cimaclinic.com

Additional identifiers

Protocol serial number
BP12/2006

Study information

Scientific Title

Study objectives

Fibromyalgia (FM) is a common illness that affects approximately 2.5 to 13% of the general population, of which the majority (10/1) are female. FM is characterised by chronic widespread pain and sleeping problems. Patients with FM frequently have other symptoms such as headaches, nocturnal jaw tightness, morning stiffness, tingling and numbness of arms and legs, irritable bowel, urinary urgency, dryness in the mouth and eyes, cold swollen hands, anxiety and /or depression. Another characteristic of FM is tenderness at palpation in defined points at the neck and lower back areas.

Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-Hydroxytryptamine [5-HT]) uptake in the brain (in contrast with most antidepressant agents), promotes neuroplasticity and reduces stress-induced atrophy of neuronal dendrites. Like the Selective Serotonin Reuptake Inhibitors (SSRIs) and in contrast with most tricyclic antidepressant agents, tianeptine does not appear to be associated with adverse cognitive, psychomotor, sleep, cardiovascular or bodyweight effects and has a low propensity for abuse. This study assesses the efficacy and safety of tianeptine in patients with FM.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Comité Ético de Investigación Clínica de Clínica, International Centre of Advanced Medicine (Centro Internacional de Medicina Avanzada [CIMA]) (Barcelona, Spain) (reference number: 0036 /2006CIMA), date of approval is 10th August 2006.

Primary study design

Interventional

Study design

A prospective double-blind, randomised, single-center, placebo-controlled, parallel group study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Fibromyalgia (FM)

Interventions

Group one - intervention group: Three month supply of oral Tianeptine (tablets) 12.5 mg every eight hours.

Group two - control group: Identical placebo every eight hours.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Tianeptine (moxonidine)

Primary outcome(s)

The primary outcome was improvement in the pain score (10 cm Visual Analog Scale [VAS]) at 24 weeks and Fibromyalgia Impact Questionnaire (FIQ) score.

Key secondary outcome(s)

1. The tender point score
2. The Hamilton Depression Anxiety inventory (HAD)
3. Short Form (SF-36) health survey.

Completion date

01/09/2007

Eligibility**Key inclusion criteria**

1. Aged from 40 to 50 years, both genders
2. Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Psychiatric illness
2. Major depression
3. Suicidal risk
4. Substance abuse
5. Pulmonary dysfunction
6. Renal impairment
7. Active cardiac disease
8. Liver disease
9. Autoimmune disease
10. Cancer
11. Sleep apnea
12. Chronic fatigue syndrome
13. Inflammatory bowel disease
14. Contraindications to tianeptine

Date of first enrolment

01/01/2007

Date of final enrolment

01/09/2007

Locations

Countries of recruitment

Spain

Study participating centre

Paseo Manuel Girona, 33

Barcelona

Spain

08034

Sponsor information

Organisation

Fundacion para la Fibromialgia y el Síndrome de Fatiga Crónica (Spain)

ROR

<https://ror.org/03p4nrj93>

Funder(s)

Funder type

Research organisation

Funder Name

Foundation for Fibromialgia and Chronic Fatigue Syndrome (Fundacion para la Fibromialgia y el Síndrome de Fatiga Crónica) (Spain)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[Study website](#)

Study website

11/11/2025

11/11/2025

No

Yes